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Background. This prospective study stratified patients by surgical resection (complete¼ NED vs incomplete¼ ED) and centrally
reviewed histology (World Health Organization [WHO] grade II vs III).
Methods. WHO grade II/NED patients received focal radiotherapy (RT) up to 59.4 Gy with 1.8 Gy/day. Grade III/NED received 4
courses of VEC (vincristine, etoposide, cyclophosphamide) after RT. ED patients received 1–4 VEC courses, second-look surgery,
and 59.4 Gy followed by an 8-Gy boost in 2 fractions on still measurable residue. NED children aged 1–3 years with grade II tumors
could receive 6 VEC courses alone.
Results. From January 2002 to December 2014, one hundred sixty consecutive children entered the protocol (median age, 4.9 y;
males, 100). Follow-up was amedian of 67months. An infratentorial origin was identified in 110 cases. After surgery, 110 patients
were NED, and 84 had grade III disease. Multiple resections were performed in 46/160 children (28.8%). A boost was given to 24/
40 ED patients achieving progression-free survival (PFS) and overall survival (OS) rates of 58.1% and 68.7%, respectively, in this
poor prognosis subgroup. For the whole series, 5-year PFS and OS rates were 65.4% and 81.1%, with no toxic deaths. On multi-
variable analysis, NED status and grade II were favorable for OS, and for PFS grade II remained favorable.
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Conclusions. In a multicenter collaboration, this trial accrued the highest number of patients published so far, and results are
comparable to the best single-institution series. The RT boost, when feasible, seemed effective in improving prognosis. Even
after multiple procedures, complete resection confirmed its prognostic strength, along with tumor grade. Biological parameters
emerging in this series will be the object of future correlatives and reports.
Keywords: boost, ependymoma, grade, prognosis, surgery.
While genomic, transcriptomic, and epigenetic research has re-
cently identified particular molecular characteristics and sub-
types of ependymoma that correlate with patients’ clinical
features, such as age and site,1–5 clinical trials conceived and
reported to date are still based on clinically prognostic factors
like the extent of resection and—for some, but not all trials—
patients’ age and tumor grade.6–8 The potential for developing
targeted, risk-adapted therapies based on recent biological dis-
coveries will probably be exploited over the next few years.
While we await the best stratification for the future, we report
here on the results obtained in 160 consecutive children be-
tween 2002 and 2014 in the second trial on intracranial epen-
dymoma conducted by the Associazione Italiana di Ematologia
e Oncologia Pediatrica (AIEOP). The therapeutic strategy was
based on previously obtained results6 and aimed to improve




Children with infratentorial or supratentorial ependymoma
were eligible for the study if they met the following criteria: (i)
age over 3 and under 21 years old; (ii) histologically confirmed
ependymoma; (iii) no prior exposure to chemotherapy (other
than steroids) or radiotherapy; (iv) normal cardiac, hepatic,
and renal function; (v) Lansky score .30; and (v) more than
one surgical procedure before enrollment was accepted and
considered part of the design to maximize resection before ad-
juvant treatment. In July 2006, the protocol was amended to
include diagnoses in children between 12 months and 3 years
of age. A second and last amendment in April 2009 prolonged
patient accrual beyond 5 years. The protocol and its amend-
ments were approved by the AIEOP and by the independent sci-
entific and/or ethical committees of all the 17 institutions
treating the children. Parents or guardians provided written
consent to the children’s participation in the study.
Study Design
This was a prospective, multi-institutional, nonrandomized
study. The treatments administered depended on surgical out-
comes and histological grade for patients with no postoperative
residual disease (Fig. 1).
Pathology Review
Histological examination was centralized for all cases before
patients were assigned to any treatment arm. Subependymomas
were not considered in this study. Cases were reviewed accord-
ing to the World Health Organization (WHO)9 criteria by 2 of the
authors (F.G., M.A), who had already provided revision for the
previous series.6
Treatment Regimens
All patients were to undergo maximal resection. All surgical re-
ports were reviewed centrally. Resection was deemed complete
when the neurosurgeon confirmed the absence of macroscopic
residual tumor at the end of the procedure and imaging
Fig. 1. (A) Treatment diagram and (B) patient flow during treatment.
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documented complete/near-complete resection, essentially as
it was described also in Merchant’s papers on the St Jude se-
ries,7,8 namely: gross total resection was defined as neurosurgi-
cal judgment of macroscopically complete resection and no
evidence of residual tumor on MRI; near-total resection was de-
fined as ,5 mm of residual tumor in greatest dimension; and
all other cases were considered as subtotal resections. Patients
were then divided into 2 treatment groups by the absence or
presence of visible residual disease (at least 5 mm in size) on
MRI performed as soon as possible after surgery. A further
stratification, identifying a third treatment arm, was applied
to patients with no residual tumor, based on tumor grade (ie,
WHO grade II or grade III).
(1) The aim was to start adjuvant treatment preferably within
4 weeks after surgery, but there was no time limit to begin
adjuvant treatment after surgery. Three different treat-
ment programs were adopted, depending on the extent of
residual disease after surgery and on the results of upfront
central pathology review, as shown in Fig. 1A. Patients
achieving a gross or near-gross total excision (no evidence
of disease¼NED) of grade II tumors were to receive focal
radiotherapy (RT) using a 3D-conformal technique, with
1.8 Gy daily up to 59.4 Gy.
(2) If patients were NED but had grade III tumors, they were
also given 4 courses of vincristine, etoposide, and cyclo-
phosphamide (VEC) chemotherapy after the same RT.
(3) Patients with residual disease (evidence of disease¼ ED)
after surgery received a maximum of 4 VEC courses, the
main aim of which was to bridge to a second-look surgery
whenever possible, and received 59.4 Gy of RT followed by
an 8-Gy boost in 2 fractions of 4 Gy each on any residual
disease still measurable in 3 planes on MRI after chemo-
therapy and/or further surgery.
Since July 2006, children over 1 and under 3 years of age re-
ceived the same treatment, except that the total radiation
dose was lowered to 54 Gy for patients younger than 18
months, and patients with grade II tumors who were unequiv-
ocally NED after surgery could be given only 6 courses of VEC
and a strict follow-up, at the local center’s discretion.
The VEC regimen consisted of vincristine (1.5 mg/m2, day 1),
cyclophosphamide (1 g/m2 infused in 1 h for 3 doses, 3 h apart,
day 1), and etoposide (100 mg/m2 infused in 2 h, days 1, 2, and 3).
VEC was delivered every 3–4 weeks both before and after RT
according to the general treatment plan. The use of granulo-
cyte colony stimulating factor as a supportive treatment was
optional. A central venous catheter was used to administer
the chemotherapy, which was to be discontinued in the event
of disease progression or unacceptable toxicity. RT was deliv-
ered using at least a 3D-conformal treatment plan and delivery
technique (all intensity-modulated RT techniques, including
tomotherapy and volumetric modulated arc therapy allowed).
The target volumes were: the postoperative tumor bed at the
primary site+residuals after surgery for gross tumor volume
(GTV); the GTV plus an anatomically confined margin of 1 cm
for the clinical target volume (CTV); and a 0.3–0.5 cm geomet-
rical expansion of the CTV for the planned target volume (PTV).
The GTV had to include the edge of the resection cavity with the
anatomically involved tissues, and gross residual tumor was
assessed on postoperative MRI, on the sequence where it was
more properly appreciated judging from its preoperative MRI
features: T1 sequence+gadolinium enhancement, T2, or
(most frequently) fluid attenuated inversion recovery.
For the RT boost, the GTV coincided with all pathological tis-
sue still measurable after surgery and chemotherapy; the CTV
overlapped the GTV; and the PTVwas a 0.2–0.3 cm geometrical
expansion of the CTV/GTV. The boost was planned to be deliv-
ered soon after completion of the full conformal treatment.
For infratentorial tumors extending beyond the foramen
magnum, the corresponding spinal cord was excluded on
reaching a cumulative physical dose of 54 Gy. In all other
cases, the cervical spinal cord that might be included in the
PTV was excluded on reaching a cumulative physical dose of
50 Gy. Children had to be treated supine using megavoltage
photons with a nominal energy ≥6 MV. Based on local policies,
immobilization devices were used for all patients to ensure
treatment reproducibility.
Staging and Imaging Follow-up
Disease extent at diagnosis was assessed by means of a spinal
MRI and CSF cytology in all patients. If more than 4 weeks
elapsed between the postoperative scan and the start of adju-
vant therapy, another radiological assessment was required.
For patients receiving only RT as adjuvant treatment after sur-
gery, MRI was performed 6 weeks after RT was completed. In
cases with residual disease, MRI was repeated after the first 2
courses of chemotherapy, before RT, after completing RT and
before the boost, if feasible, and 6 weeks afterward. In cases
undergoing second-look surgery, MRI was repeated as soon
as possible after the surgical procedure. For patients with no re-
sidual disease given chemotherapy after RT, MRI was repeated
after 2 courses of VEC and again 1 month after completing the
treatment.
Radiological follow-up included MRI every 3 months for the
first 2 years after completing the treatment, then every 4
months in the third and fourth years, and then every 6 months
thereafter.
Statistical Methods
All patients were included in our analysis, regardless of whether
or not they were compliant with the treatment program. The
main endpoints of the study were overall survival (OS) and
progression-free survival (PFS) for the whole case series. We
also assessed local tumor control for the 3 treatment sub-
groups: (i) after conformal RT, (ii) chemotherapy and/or second-
look surgery followed by RT+boost, and (iii) chemotherapy
after conformal RT. The OS time was computed as the time
elapsing from the date of the first diagnostic radiological
exam to the date of death due to any cause, censoring at the
time of the latest follow-up for patients still alive. The PFS time
was computed as the interval between the date of the first di-
agnostic radiological exam and the date when progression
(local or distant, whichever occurred first) was identified, cen-
soring at the latest follow-up for patients remaining in first
complete remission. OS and PFS curves were estimated using
the Kaplan–Meier method and compared with the log-rank
test. We also separately estimated the cumulative incidence
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Conclusions. In a multicenter collaboration, this trial accrued the highest number of patients published so far, and results are
comparable to the best single-institution series. The RT boost, when feasible, seemed effective in improving prognosis. Even
after multiple procedures, complete resection confirmed its prognostic strength, along with tumor grade. Biological parameters
emerging in this series will be the object of future correlatives and reports.
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While genomic, transcriptomic, and epigenetic research has re-
cently identified particular molecular characteristics and sub-
types of ependymoma that correlate with patients’ clinical
features, such as age and site,1–5 clinical trials conceived and
reported to date are still based on clinically prognostic factors
like the extent of resection and—for some, but not all trials—
patients’ age and tumor grade.6–8 The potential for developing
targeted, risk-adapted therapies based on recent biological dis-
coveries will probably be exploited over the next few years.
While we await the best stratification for the future, we report
here on the results obtained in 160 consecutive children be-
tween 2002 and 2014 in the second trial on intracranial epen-
dymoma conducted by the Associazione Italiana di Ematologia
e Oncologia Pediatrica (AIEOP). The therapeutic strategy was
based on previously obtained results6 and aimed to improve




Children with infratentorial or supratentorial ependymoma
were eligible for the study if they met the following criteria: (i)
age over 3 and under 21 years old; (ii) histologically confirmed
ependymoma; (iii) no prior exposure to chemotherapy (other
than steroids) or radiotherapy; (iv) normal cardiac, hepatic,
and renal function; (v) Lansky score .30; and (v) more than
one surgical procedure before enrollment was accepted and
considered part of the design to maximize resection before ad-
juvant treatment. In July 2006, the protocol was amended to
include diagnoses in children between 12 months and 3 years
of age. A second and last amendment in April 2009 prolonged
patient accrual beyond 5 years. The protocol and its amend-
ments were approved by the AIEOP and by the independent sci-
entific and/or ethical committees of all the 17 institutions
treating the children. Parents or guardians provided written
consent to the children’s participation in the study.
Study Design
This was a prospective, multi-institutional, nonrandomized
study. The treatments administered depended on surgical out-
comes and histological grade for patients with no postoperative
residual disease (Fig. 1).
Pathology Review
Histological examination was centralized for all cases before
patients were assigned to any treatment arm. Subependymomas
were not considered in this study. Cases were reviewed accord-
ing to the World Health Organization (WHO)9 criteria by 2 of the
authors (F.G., M.A), who had already provided revision for the
previous series.6
Treatment Regimens
All patients were to undergo maximal resection. All surgical re-
ports were reviewed centrally. Resection was deemed complete
when the neurosurgeon confirmed the absence of macroscopic
residual tumor at the end of the procedure and imaging
Fig. 1. (A) Treatment diagram and (B) patient flow during treatment.
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documented complete/near-complete resection, essentially as
it was described also in Merchant’s papers on the St Jude se-
ries,7,8 namely: gross total resection was defined as neurosurgi-
cal judgment of macroscopically complete resection and no
evidence of residual tumor on MRI; near-total resection was de-
fined as ,5 mm of residual tumor in greatest dimension; and
all other cases were considered as subtotal resections. Patients
were then divided into 2 treatment groups by the absence or
presence of visible residual disease (at least 5 mm in size) on
MRI performed as soon as possible after surgery. A further
stratification, identifying a third treatment arm, was applied
to patients with no residual tumor, based on tumor grade (ie,
WHO grade II or grade III).
(1) The aim was to start adjuvant treatment preferably within
4 weeks after surgery, but there was no time limit to begin
adjuvant treatment after surgery. Three different treat-
ment programs were adopted, depending on the extent of
residual disease after surgery and on the results of upfront
central pathology review, as shown in Fig. 1A. Patients
achieving a gross or near-gross total excision (no evidence
of disease¼NED) of grade II tumors were to receive focal
radiotherapy (RT) using a 3D-conformal technique, with
1.8 Gy daily up to 59.4 Gy.
(2) If patients were NED but had grade III tumors, they were
also given 4 courses of vincristine, etoposide, and cyclo-
phosphamide (VEC) chemotherapy after the same RT.
(3) Patients with residual disease (evidence of disease¼ ED)
after surgery received a maximum of 4 VEC courses, the
main aim of which was to bridge to a second-look surgery
whenever possible, and received 59.4 Gy of RT followed by
an 8-Gy boost in 2 fractions of 4 Gy each on any residual
disease still measurable in 3 planes on MRI after chemo-
therapy and/or further surgery.
Since July 2006, children over 1 and under 3 years of age re-
ceived the same treatment, except that the total radiation
dose was lowered to 54 Gy for patients younger than 18
months, and patients with grade II tumors who were unequiv-
ocally NED after surgery could be given only 6 courses of VEC
and a strict follow-up, at the local center’s discretion.
The VEC regimen consisted of vincristine (1.5 mg/m2, day 1),
cyclophosphamide (1 g/m2 infused in 1 h for 3 doses, 3 h apart,
day 1), and etoposide (100 mg/m2 infused in 2 h, days 1, 2, and 3).
VEC was delivered every 3–4 weeks both before and after RT
according to the general treatment plan. The use of granulo-
cyte colony stimulating factor as a supportive treatment was
optional. A central venous catheter was used to administer
the chemotherapy, which was to be discontinued in the event
of disease progression or unacceptable toxicity. RT was deliv-
ered using at least a 3D-conformal treatment plan and delivery
technique (all intensity-modulated RT techniques, including
tomotherapy and volumetric modulated arc therapy allowed).
The target volumes were: the postoperative tumor bed at the
primary site+residuals after surgery for gross tumor volume
(GTV); the GTV plus an anatomically confined margin of 1 cm
for the clinical target volume (CTV); and a 0.3–0.5 cm geomet-
rical expansion of the CTV for the planned target volume (PTV).
The GTV had to include the edge of the resection cavity with the
anatomically involved tissues, and gross residual tumor was
assessed on postoperative MRI, on the sequence where it was
more properly appreciated judging from its preoperative MRI
features: T1 sequence+gadolinium enhancement, T2, or
(most frequently) fluid attenuated inversion recovery.
For the RT boost, the GTV coincided with all pathological tis-
sue still measurable after surgery and chemotherapy; the CTV
overlapped the GTV; and the PTVwas a 0.2–0.3 cm geometrical
expansion of the CTV/GTV. The boost was planned to be deliv-
ered soon after completion of the full conformal treatment.
For infratentorial tumors extending beyond the foramen
magnum, the corresponding spinal cord was excluded on
reaching a cumulative physical dose of 54 Gy. In all other
cases, the cervical spinal cord that might be included in the
PTV was excluded on reaching a cumulative physical dose of
50 Gy. Children had to be treated supine using megavoltage
photons with a nominal energy ≥6 MV. Based on local policies,
immobilization devices were used for all patients to ensure
treatment reproducibility.
Staging and Imaging Follow-up
Disease extent at diagnosis was assessed by means of a spinal
MRI and CSF cytology in all patients. If more than 4 weeks
elapsed between the postoperative scan and the start of adju-
vant therapy, another radiological assessment was required.
For patients receiving only RT as adjuvant treatment after sur-
gery, MRI was performed 6 weeks after RT was completed. In
cases with residual disease, MRI was repeated after the first 2
courses of chemotherapy, before RT, after completing RT and
before the boost, if feasible, and 6 weeks afterward. In cases
undergoing second-look surgery, MRI was repeated as soon
as possible after the surgical procedure. For patients with no re-
sidual disease given chemotherapy after RT, MRI was repeated
after 2 courses of VEC and again 1 month after completing the
treatment.
Radiological follow-up included MRI every 3 months for the
first 2 years after completing the treatment, then every 4
months in the third and fourth years, and then every 6 months
thereafter.
Statistical Methods
All patients were included in our analysis, regardless of whether
or not they were compliant with the treatment program. The
main endpoints of the study were overall survival (OS) and
progression-free survival (PFS) for the whole case series. We
also assessed local tumor control for the 3 treatment sub-
groups: (i) after conformal RT, (ii) chemotherapy and/or second-
look surgery followed by RT+boost, and (iii) chemotherapy
after conformal RT. The OS time was computed as the time
elapsing from the date of the first diagnostic radiological
exam to the date of death due to any cause, censoring at the
time of the latest follow-up for patients still alive. The PFS time
was computed as the interval between the date of the first di-
agnostic radiological exam and the date when progression
(local or distant, whichever occurred first) was identified, cen-
soring at the latest follow-up for patients remaining in first
complete remission. OS and PFS curves were estimated using
the Kaplan–Meier method and compared with the log-rank
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of local and distant progression, conducting the analyses in a
competing risks framework: local progression concurrent with
distant progression was classified as distant progression, and
the cumulative incidence curves were estimated and compared
using Gray’s test.10
Multivariable analyses were run to investigate the joint prog-
nostic effect on OS and PFS of patient- and tumor-related char-
acteristics, such as patients’ gender and age, tumor site and
grade, need for a shunt, residual tumor after first surgery, resid-
ual tumor after second-look surgery (ie, before RT), and interval
between surgery and chemotherapy. For both of the endpoints
investigated, the number of events (deaths or disease pro-
gressions) for each predictor variable was very low, and this
hampered the reliability of the results emerging from the mul-
tivariable regression model.11 To select the most informative
variables from among the previously defined set of predictors,
we therefore resorted to using “component-wise gradient
boosting,”12 as implemented in the R library “mboost,”13
which is a machine learning method for optimizing prediction
accuracy and selecting variables during the fitting process.
The association between pairs of categorical variables or be-
tween continuous and categorical variables was assessed




Between January 2002 and December 2014 (when patient ac-
crual was stopped), 160 consecutive children with a median
age of 4.9 years (range, 1–17.8 y) entered the protocol. All his-
tological diagnoses were obtained at the local pathology ser-
vice, and all tumor samples were centrally reviewed (as
explained above), and treatments were tailored in the light of
said review. The main characteristics of the patients in this se-
ries are given in Table 1, as a whole and by extent of resection,
which was complete for 110 patients.
Tumor Location
Tumors originated supratentorially in 50 children and infraten-
torially in the remaining 110. At diagnosis, distant spread was
identified in 2 patients with completely resected infratentorial
tumors: one had further nodules in the third ventricle, the
conus medullaris, and the spine at T6; the other had a cauda
nodule that was removed soon after first excision of the prima-
ry tumor. Their CSF cytological examinations were negative for
tumor cells, thus confirming the doubtful utility of this common
diagnostic procedure.14,15
Extent of Resection
After initial surgery, residual tumor was documented in 50/160
(31%) children, based on combined neurosurgical reports and
postoperative imaging studies.
Eleven children had achieved a complete resection after 2
surgical procedures (including the girl with the cauda metasta-
sis). A significant association emerged between tumor location
and extent of resection: residual tumor was detected in 40/110
(36.4%) infratentorial tumors, and in 10/50 (20.0%) supraten-
torial neoplasms (P¼ .044).
In 60/160 children, a permanent ventricular shunt was
needed to manage hydrocephalus, and this was significantly
associated with tumor location: a shunt was needed for 51/
110 (46.4%) patients with infratentorial tumors, and 9/50
(18.0%) patients with supratentorial disease (P¼ .001).
Histology
Seventy-six tumors (47.5% of the sample) were defined as
“classic” (WHO grade II) ependymomas, while 84 (52.5%)
were “anaplastic” (WHO grade III).
The percentage of anaplastic ependymomas differed at the
2 locations: 49/110 (44.5%) tumors arising infratentorially and
35/50 (70%) of supratentorial tumors were anaplastic (P¼
.004). There was no significant difference in tumor histology be-
tween the group of NED patients, 62/110 (56.4%) of whom had
anaplastic tumors, and the ED group, where 22/50 (44.0%) had
the anaplastic form (P¼ .173).
Patients’ Gender and Age
Gender was not significantly associated with tumor origin, extent
of resection, tumor grade, or need for a shunt (data not shown).
Age was significantly associated with tumor origin: the per-
centage of patients with infratentorial tumors was higher
among those aged ,3 years (40/45 [88.9%] vs 70/115 [60.9%]
patients≥3 y old; P¼ .001). Age was also significantly associated
with tumor grade (P¼ .034), the percentage of patients with
grade III tumors being higher among those aged ,3 years
(30/45 [66.7%] vs 54/115 [47.0%] patients aged≥3 y). The pro-
portion of patients needing a ventricular shunt was also signifi-
cantly higher among the younger patients (23/45 [51.1%] vs
37/115 [32.2%]; P¼ .030). Age was not significantly associated
with the extent of resection, however (P¼ .999).








Female 46 (41.8%) 14 (28.0%) 60 (37.5%)




5.3 (2.8–9.3) 4.2 (2.7–7.2) 4.9 (2.8–9.1)
Under 3 y 31 (28.2%) 14 (28.0%) 45 (28.1%)
3 y or over 79 (71.8%) 36 (72.0%) 115 (71.9%)
Tumor location
Supratentorial 40 (36.4%) 10 (20.0%) 50 (31.2%)
Infratentorial 70 (63.6%) 40 (80.0%) 110 (68.8%)
WHO grade
Grade II/classic 48 (43.6%) 28 (56.0%) 76 (47.5%)
Grade III/anaplastic 62 (56.4%) 22 (44.0%) 84 (52.5%)
Ventricular shunt
No 84 (76.4%) 16 (23.6%) 100 (62.5%)
Yes 26 (23.6%) 34 (68.0%) 60 (37.5%)
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Adjuvant Treatment
Figure 1B shows the treatment diagram for the series as a
whole.
Of the 110 NED children, 3 with grade III anaplastic ependy-
moma did not receive chemotherapy after radiation due to a
local physician violating the protocol (in 2 cases) or to the pa-
tient’s poor neurological conditions (in 1). Two children under 3
years of age at diagnosis with a grade II classic histology re-
ceived only VEC chemotherapy after complete resection.
Of the 50 ED patients, 27 underwent further surgical proce-
dure(s) after 1–4 courses of VEC. Number of VEC courses was
not compulsory because the main chemotherapy aim, in pa-
tients with residual disease, was to bridge to second-look sur-
gery. Complete resection was achieved in 10 cases. Another 2
patients were submitted to complete resection of tumor resid-
uals after RT, as will be below further described.
Second-look surgery
Including second-look procedures performed soon after a first
excision, before any adjuvant treatment, a total of 100 proce-
dures were performed in 46/160 children (28.8%), with 40 pa-
tients undergoing surgery twice, 5 children 3 times, and 1 child
5 times. One of these patients had second-look surgery during
RTon a cystic mass, while residual tumor was removed in 2 chil-
dren 10 and 14 months after they had received the RT boost.
This approach achieved an additional 23 complete resections
with respect to the status after the first surgical procedure.
Of the 40 patients still with ED when their RT started, 24 had
RT boosts, as per our protocol, after completing conformal RT.
In one other child, a neurosurgeon prescribed the RT boost on
what he contoured as an area of microscopic residual disease,
even though second-look surgery had been judged complete
(so this RT boost went against the protocol). Sixteen remaining
children with ED did not receive the boost for the following rea-
sons: (i) at the radiotherapist’s discretion, due to a large resid-
ual tumor or anatomical constraints in 9 cases; (ii) because no
residual tumor was clearly identifiable after chemotherapy in 6;
and (iii) due to metastatic disease in 1.
Of the 158 patients given adjuvant radiotherapy after sur-
gery, 140 received 59.4 Gy, another 8 children under 18months
of age at diagnosis received 54 Gy, and 8 patients received
doses of 50.5–57.6 Gy, with a median of 55.8 Gy. The 2 pa-
tients with metastatic disease were treated differently. The pa-
tient with the complete resection of both the primary tumor
and the spinal metastasis, who was 12 years old, received cra-
niospinal irradiation at a total dose of 36 Gy, in 20 daily frac-
tions of 1.8 Gy, with a boost up to 54 Gy on the primary
tumor bed and up to 50.4 Gy on the secondary site. The
other child, 6 years old at diagnosis, received 59.4 Gy on the pri-
mary tumor bed because the other sites were not ascertained
for sure to be metastases, thereafter, when they did grow, he
had surgery on the spinal nodules and received 59.4 Gy on
the third ventricle metastasis and 36 Gy on the spine.
The PFS and OS of the 16 patients receiving different radia-
tion doses on their primary tumors did not differ statistically
from the other 141 patients.
Of the 2 children receiving only chemotherapy as adjuvant
treatment, one was alive in continuous remission at 77 months
after diagnosis, while the other had a local relapse after 19
months, was reoperated on and irradiated at the total dose
of 59.4 Gy, and was alive in second remission at 118 months
at the time of this report.
Treatment Toxicity
At least one neurological deficit and/or hemorrhagic or infec-
tious episode was reported in 63/160 patients after surgery.
Among those, gastrostomy or a nasogastric tube was to be
put in place in 5 patients and tracheostomy in 3, while postsur-
gical mutism was detected in 3 cases. Adjuvant treatment
began more than 6 weeks after surgery for 63/160 patients.
In 36 cases, this was due to recovery from postsurgical compli-
cations, mainly low cranial nerve deficits and CSF dynamic al-
teration, while in the remaining 27 patients it was a referral
delay. None of the patients had to abandon the adjuvant treat-
ment due to these events. For the sample as a whole, the time
elapsing between surgery and adjuvant treatment ranged from
11 to 210 days, median 42 days. This interval had no prognostic
impact.
None of the children died due to adjuvant treatment.
Second-look surgery was followed by a deterioration in neu-
rological cerebellar and lower cranial nerve function in 4/46 pa-
tients and by bleeding in 1. At the time of this report, all
neurological impairments had reportedly improved.
Chemotherapy-related toxicity overlapped with the situa-
tion seen in the previous protocol when it was used before
RT,6 and did not differ when the 4 VEC schedules were admin-
istered after RT.
Progression-free Survival and Overall Survival
The median follow-up was 67 months (95% CI: 59–78 mo;
interquartile range: 41–110 mo). For the whole series, the
5-year PFS and OS were respectively 65.4% (95% CI: 57.7%–
74.0%) and 81.1% (95% CI: 74.6%–88.2%) (Fig. 2). The
Fig. 2. Kaplan–Meier PFS and OS curves for the whole series.
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of local and distant progression, conducting the analyses in a
competing risks framework: local progression concurrent with
distant progression was classified as distant progression, and
the cumulative incidence curves were estimated and compared
using Gray’s test.10
Multivariable analyses were run to investigate the joint prog-
nostic effect on OS and PFS of patient- and tumor-related char-
acteristics, such as patients’ gender and age, tumor site and
grade, need for a shunt, residual tumor after first surgery, resid-
ual tumor after second-look surgery (ie, before RT), and interval
between surgery and chemotherapy. For both of the endpoints
investigated, the number of events (deaths or disease pro-
gressions) for each predictor variable was very low, and this
hampered the reliability of the results emerging from the mul-
tivariable regression model.11 To select the most informative
variables from among the previously defined set of predictors,
we therefore resorted to using “component-wise gradient
boosting,”12 as implemented in the R library “mboost,”13
which is a machine learning method for optimizing prediction
accuracy and selecting variables during the fitting process.
The association between pairs of categorical variables or be-
tween continuous and categorical variables was assessed




Between January 2002 and December 2014 (when patient ac-
crual was stopped), 160 consecutive children with a median
age of 4.9 years (range, 1–17.8 y) entered the protocol. All his-
tological diagnoses were obtained at the local pathology ser-
vice, and all tumor samples were centrally reviewed (as
explained above), and treatments were tailored in the light of
said review. The main characteristics of the patients in this se-
ries are given in Table 1, as a whole and by extent of resection,
which was complete for 110 patients.
Tumor Location
Tumors originated supratentorially in 50 children and infraten-
torially in the remaining 110. At diagnosis, distant spread was
identified in 2 patients with completely resected infratentorial
tumors: one had further nodules in the third ventricle, the
conus medullaris, and the spine at T6; the other had a cauda
nodule that was removed soon after first excision of the prima-
ry tumor. Their CSF cytological examinations were negative for
tumor cells, thus confirming the doubtful utility of this common
diagnostic procedure.14,15
Extent of Resection
After initial surgery, residual tumor was documented in 50/160
(31%) children, based on combined neurosurgical reports and
postoperative imaging studies.
Eleven children had achieved a complete resection after 2
surgical procedures (including the girl with the cauda metasta-
sis). A significant association emerged between tumor location
and extent of resection: residual tumor was detected in 40/110
(36.4%) infratentorial tumors, and in 10/50 (20.0%) supraten-
torial neoplasms (P¼ .044).
In 60/160 children, a permanent ventricular shunt was
needed to manage hydrocephalus, and this was significantly
associated with tumor location: a shunt was needed for 51/
110 (46.4%) patients with infratentorial tumors, and 9/50
(18.0%) patients with supratentorial disease (P¼ .001).
Histology
Seventy-six tumors (47.5% of the sample) were defined as
“classic” (WHO grade II) ependymomas, while 84 (52.5%)
were “anaplastic” (WHO grade III).
The percentage of anaplastic ependymomas differed at the
2 locations: 49/110 (44.5%) tumors arising infratentorially and
35/50 (70%) of supratentorial tumors were anaplastic (P¼
.004). There was no significant difference in tumor histology be-
tween the group of NED patients, 62/110 (56.4%) of whom had
anaplastic tumors, and the ED group, where 22/50 (44.0%) had
the anaplastic form (P¼ .173).
Patients’ Gender and Age
Gender was not significantly associated with tumor origin, extent
of resection, tumor grade, or need for a shunt (data not shown).
Age was significantly associated with tumor origin: the per-
centage of patients with infratentorial tumors was higher
among those aged ,3 years (40/45 [88.9%] vs 70/115 [60.9%]
patients≥3 y old; P¼ .001). Age was also significantly associated
with tumor grade (P¼ .034), the percentage of patients with
grade III tumors being higher among those aged ,3 years
(30/45 [66.7%] vs 54/115 [47.0%] patients aged≥3 y). The pro-
portion of patients needing a ventricular shunt was also signifi-
cantly higher among the younger patients (23/45 [51.1%] vs
37/115 [32.2%]; P¼ .030). Age was not significantly associated
with the extent of resection, however (P¼ .999).








Female 46 (41.8%) 14 (28.0%) 60 (37.5%)




5.3 (2.8–9.3) 4.2 (2.7–7.2) 4.9 (2.8–9.1)
Under 3 y 31 (28.2%) 14 (28.0%) 45 (28.1%)
3 y or over 79 (71.8%) 36 (72.0%) 115 (71.9%)
Tumor location
Supratentorial 40 (36.4%) 10 (20.0%) 50 (31.2%)
Infratentorial 70 (63.6%) 40 (80.0%) 110 (68.8%)
WHO grade
Grade II/classic 48 (43.6%) 28 (56.0%) 76 (47.5%)
Grade III/anaplastic 62 (56.4%) 22 (44.0%) 84 (52.5%)
Ventricular shunt
No 84 (76.4%) 16 (23.6%) 100 (62.5%)
Yes 26 (23.6%) 34 (68.0%) 60 (37.5%)
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Adjuvant Treatment
Figure 1B shows the treatment diagram for the series as a
whole.
Of the 110 NED children, 3 with grade III anaplastic ependy-
moma did not receive chemotherapy after radiation due to a
local physician violating the protocol (in 2 cases) or to the pa-
tient’s poor neurological conditions (in 1). Two children under 3
years of age at diagnosis with a grade II classic histology re-
ceived only VEC chemotherapy after complete resection.
Of the 50 ED patients, 27 underwent further surgical proce-
dure(s) after 1–4 courses of VEC. Number of VEC courses was
not compulsory because the main chemotherapy aim, in pa-
tients with residual disease, was to bridge to second-look sur-
gery. Complete resection was achieved in 10 cases. Another 2
patients were submitted to complete resection of tumor resid-
uals after RT, as will be below further described.
Second-look surgery
Including second-look procedures performed soon after a first
excision, before any adjuvant treatment, a total of 100 proce-
dures were performed in 46/160 children (28.8%), with 40 pa-
tients undergoing surgery twice, 5 children 3 times, and 1 child
5 times. One of these patients had second-look surgery during
RTon a cystic mass, while residual tumor was removed in 2 chil-
dren 10 and 14 months after they had received the RT boost.
This approach achieved an additional 23 complete resections
with respect to the status after the first surgical procedure.
Of the 40 patients still with ED when their RT started, 24 had
RT boosts, as per our protocol, after completing conformal RT.
In one other child, a neurosurgeon prescribed the RT boost on
what he contoured as an area of microscopic residual disease,
even though second-look surgery had been judged complete
(so this RT boost went against the protocol). Sixteen remaining
children with ED did not receive the boost for the following rea-
sons: (i) at the radiotherapist’s discretion, due to a large resid-
ual tumor or anatomical constraints in 9 cases; (ii) because no
residual tumor was clearly identifiable after chemotherapy in 6;
and (iii) due to metastatic disease in 1.
Of the 158 patients given adjuvant radiotherapy after sur-
gery, 140 received 59.4 Gy, another 8 children under 18months
of age at diagnosis received 54 Gy, and 8 patients received
doses of 50.5–57.6 Gy, with a median of 55.8 Gy. The 2 pa-
tients with metastatic disease were treated differently. The pa-
tient with the complete resection of both the primary tumor
and the spinal metastasis, who was 12 years old, received cra-
niospinal irradiation at a total dose of 36 Gy, in 20 daily frac-
tions of 1.8 Gy, with a boost up to 54 Gy on the primary
tumor bed and up to 50.4 Gy on the secondary site. The
other child, 6 years old at diagnosis, received 59.4 Gy on the pri-
mary tumor bed because the other sites were not ascertained
for sure to be metastases, thereafter, when they did grow, he
had surgery on the spinal nodules and received 59.4 Gy on
the third ventricle metastasis and 36 Gy on the spine.
The PFS and OS of the 16 patients receiving different radia-
tion doses on their primary tumors did not differ statistically
from the other 141 patients.
Of the 2 children receiving only chemotherapy as adjuvant
treatment, one was alive in continuous remission at 77 months
after diagnosis, while the other had a local relapse after 19
months, was reoperated on and irradiated at the total dose
of 59.4 Gy, and was alive in second remission at 118 months
at the time of this report.
Treatment Toxicity
At least one neurological deficit and/or hemorrhagic or infec-
tious episode was reported in 63/160 patients after surgery.
Among those, gastrostomy or a nasogastric tube was to be
put in place in 5 patients and tracheostomy in 3, while postsur-
gical mutism was detected in 3 cases. Adjuvant treatment
began more than 6 weeks after surgery for 63/160 patients.
In 36 cases, this was due to recovery from postsurgical compli-
cations, mainly low cranial nerve deficits and CSF dynamic al-
teration, while in the remaining 27 patients it was a referral
delay. None of the patients had to abandon the adjuvant treat-
ment due to these events. For the sample as a whole, the time
elapsing between surgery and adjuvant treatment ranged from
11 to 210 days, median 42 days. This interval had no prognostic
impact.
None of the children died due to adjuvant treatment.
Second-look surgery was followed by a deterioration in neu-
rological cerebellar and lower cranial nerve function in 4/46 pa-
tients and by bleeding in 1. At the time of this report, all
neurological impairments had reportedly improved.
Chemotherapy-related toxicity overlapped with the situa-
tion seen in the previous protocol when it was used before
RT,6 and did not differ when the 4 VEC schedules were admin-
istered after RT.
Progression-free Survival and Overall Survival
The median follow-up was 67 months (95% CI: 59–78 mo;
interquartile range: 41–110 mo). For the whole series, the
5-year PFS and OS were respectively 65.4% (95% CI: 57.7%–
74.0%) and 81.1% (95% CI: 74.6%–88.2%) (Fig. 2). The
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5-year probability of local relapse was 20.7% (95% CI: 14.8%–
29.1%) and for distant metastasis it was 13.9% (95% CI:
9.2%–21.0%). Combined relapses were detected in 3 cases,
as shown by Fig. 1B.
The median time to progression was 19 months (4–103 mo),
23 months for local, and 17 months for distant relapse.
Based on the surgical results at the time of starting adjuvant
treatment, the 5-year PFS and OS rates were respectively 70.8%
(95% CI: 66%–75.6%) and 86.6% (95% CI: 82.9%–90.3%) for
patients without residual disease, and 53% (95% CI: 39.7%–
71%) and 68.6% (95% CI: 55.7%–84.6%) for patients with re-
sidual disease.
Table 2 shows the 5-year PFS and OS estimates by the differ-
ent prognostic variables. Female patients had a significantly
better PFS (P¼ .005) and OS (P¼ .031) than males. Having
found significant results for PFS, we separately estimated the
cumulative incidence of local and distant relapse. The local re-
lapse rate was significantly lower in females (5-year cumulative
incidence estimate: 3.4%; 95% CI: 0.9%–13.3%) than in males
(31.8%; 95% CI: 22.9%–44.0%; P, .0001), while for distant
metastases there was no significant difference between the 2
groups, with 16.3% (95% CI: 8.8%–30.1%) in females, and
12.4% (95% CI: 7.1%–21.7%) in males (P¼ .597).
There were no significant differences in PFS by patients’ age,
but the 2 groups (,3 vs ≥3 y old) differed significantly in terms
of OS (Table 2). PFS did not differ significantly by tumor location
either (infratentorial vs supratentorial), whereas OS did (P¼
.039). PFS was significantly better for grade II tumor patients
without residual disease than for grade III tumor patients
with or without residues, while the latter shared much the
same PFS (Fig. 3A; P¼ .025); the OS also differed significantly
between these 3 groups (see different curves in Fig. 3B; P¼
.007). Figure 1B shows the pattern of tumor relapse: there
was no significant difference as regards local relapse (P¼
.309; Supplementary Fig. S1), but patients with residual disease
after surgery had the highest incidence of local recurrence
(5-year estimate: 28.9%; 95% CI: 17.6%–47.4%), followed by
grade III tumor patients without residues (19.4%; 11.3%–
33.5%) and grade II patients without residues (13.5%; 5.8%–
31.7%). Distant relapses were significantly more common
among patients with grade III tumors—whether they were
without residues (18.7%; 10.8%–32.1%) or with residual dis-
ease (17.9%; 9.4%–34.1%)—than in grade II patients without
residues (2.3%; 0.3%–16.9%) (P¼ .048). Considering grade in-
fluence on patients’ PFS and OS according to tumor location,
neither PFS nor OS was influenced in supratentorial tumor pa-
tients. There was instead a statistically significant difference for
patients whose tumor originated infratentorially in both PFS
(5-year estimate: 73.3%, 95% CI: 61.0%–88.2% if grade II;
and 47.8%, 95% CI: 35.0%–65.2% if grade III, P¼ .0047)
and OS (5-year estimate: 89.7%, 95% CI: 81.5%–98.7% if
grade II; and 65.1%, 95% CI: 52.1%–81.4% if grade III, P¼
.009).
Considering the patients’ status before RT, with a further 10
patients becoming disease free after chemotherapy and
second-look surgery, the PFS and OS differed statistically be-
tween the 120 patients who were NED and the 40 who were
still ED. The 5-year estimates for local relapse were 16.9%
Table 2. Kaplan–Meier PFS and OS
PFS OS
5-y Estimate (CI) P (log-rank) 5-y Estimate (CI) P (log-rank)
Gender .005 .031
Female 80.3% (70.4%–91.6%) 89.3% (81.5%–97.8%)
Male 55.8% (45.9%–67.9%) 75.7% (66.6%–86.0%)
Age .164 .035
,3 y 57.6% (43.1%–77.2%) 70.3% (56.3%–87.8%)
≥3 y 67.9% (59.3%–77.8%) 84.8% (77.9%–92.3%)
Tumor location .116 .039
Infratentorial 60.9% (51.4%–72.2%) 77.7% (69.4%–87.0%)
Supratentorial 73.8% (61.9%–87.9%) 88.1% (78.8%–98.6%)
Residual disease after surgery .025 .007
No residual grade II 84.1% (72.9%–97.0%) 97.6% (93.1%–100.0%)
No residual grade III 61.9% (50.3%–76.1%) 79.1% (68.6%–91.2%)
Residual, any grade 53.1% (39.7%–71.0%) 68.6% (55.7%–84.6%)
Status before radiation therapy .011 .001
NED 72.1% (63.8%–81.5%) 87.8% (81.5%–94.6%)
ED 45.3% (30.9%–66.2%) 61.2% (46.5%–80.5%)
WHO grade .018 .031
Grade II/classic 75.3% (64.9%–87.3%) 90.5% (83.4%–98.1%)
Grade III/anaplastic 57.0% (46.7%–69.6%) 73.3% (63.5%–84.6%)
Ventricular shunt .349 .019
No 68.9% (59.8%–79.4%) 85.7% (78.4%–93.6%)
Yes 58.4% (45.5%–74.9%) 72.5% (60.6%–86.6%)
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(95% CI: 10.8%–26.4%) in NED patients and 32.5% (95% CI:
19.5%–54.0%) in still-ED patients (P¼ .119). The correspond-
ing cumulative incidence estimates for distant metastases
were 11.1% (95% CI: 6.5%–18.9%) and 22.3% (95% CI:
11.9%–41.9%) (P¼ .105).
When the 2 children who achieved NED status after RT boost
were included, there were 23 patients who came to have NED
after accrual thanks to multiple surgical procedures and che-
motherapy; their prognoses, in terms of both PFS and OS,
were much the same as for patients who had NED after a single
excision (data not shown).
Among the 40 patients with ED before RT, 24 received the
prescribed boost after the standard course of radiation
(Fig. 1B): the 5-year estimates for PFS were 58.1% (95% CI:
39.1%–86.4%) for the latter 24 patients, and 43.0% (95%
CI: 43.0%–78.6%) for the 16 not given the boost (P¼ .344),
while the OS estimates were 68.7% (95% CI: 50.5%–93.4%)
versus 50.2% (95% CI: 29.8%–84.6%) (P ¼ .346). A WHO
grade II classic ependymoma was associated with the best
PFS and OS in our sample: the PFS was 75.3% (95% CI:
64.9%–87.3%) and 57.0% (95% CI: 46.7%–69.6%) for
grade II and grade III tumor patients, respectively (P ¼
.018); and the OS was 90.5% (95% CI: 86.8%–98.1%) and
73.3% (95% CI: 63.5%–84.6%) for grade II and grade III
tumor patients, respectively (P¼ .031). The 5-year estimates
for local relapse were 17.3% (95% CI: 9.6%–31.0%) in the
grade II subgroup and 23.7% (95% CI: 15.6%–35.9%) for pa-
tients with ED (P¼ .281). The corresponding cumulative inci-
dence estimates for distant metastases were 7.4% (95% CI:
3.2%–17.5%) and 19.3% (95% CI: 12.1%–30.6%) (P¼ .052).
Among the 45 patients aged below 3 years at diagnosis, 16
had grade II tumors. Differently from older children, their
PFS and OSwere not significantly better than those of children
with grade III tumors.
Table 3 shows the results of Cox’s multivariate analysis, after
selecting prognostic variables with the boosting algorithm. The
most influential variables identified by the algorithm were the
same on both of the endpoints considered, but tumor grade
had themost influence on PFS, followed by gender, NED/ED sta-
tus before RT, and tumor location; as for OS, the most influen-
tial variable was NED/ED status before RT, followed by tumor
grade, tumor location, and gender.
Discussion
After the previous Italian experience showing quite a good
prognosis for completely resected classic ependymoma,6
Fig. 3. (A) Kaplan-Meier PFS and (B) OS curves by outcome of first
surgery.
Table 3. Cox multivariate model analyses of PFS and OS
PFS OS
Hazard Ratio (CI) P (Wald test) Hazard Ratio (CI) P (Wald test)
Gender .063 .251
Male vs female 1.93 (0.96, 3.86) 1.72 (0.68, 4.37)
Tumor location .186 .076
Infratentorial vs supratentorial 1.59 (0.80, 3.14) 2.47 (0.91, 6.72)
Status before radiation therapy .058 .009
ED vs NED 1.78 (0.98, 3.22) 2.73 (1.28, 5.83)
WHO grade .012 .009
Grade III vs II 2.20 (1.19, 4.06) 3.03 (1.31, 6.98)
Massimino et al.: Management of pediatric intracranial ependymoma
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5-year probability of local relapse was 20.7% (95% CI: 14.8%–
29.1%) and for distant metastasis it was 13.9% (95% CI:
9.2%–21.0%). Combined relapses were detected in 3 cases,
as shown by Fig. 1B.
The median time to progression was 19 months (4–103 mo),
23 months for local, and 17 months for distant relapse.
Based on the surgical results at the time of starting adjuvant
treatment, the 5-year PFS and OS rates were respectively 70.8%
(95% CI: 66%–75.6%) and 86.6% (95% CI: 82.9%–90.3%) for
patients without residual disease, and 53% (95% CI: 39.7%–
71%) and 68.6% (95% CI: 55.7%–84.6%) for patients with re-
sidual disease.
Table 2 shows the 5-year PFS and OS estimates by the differ-
ent prognostic variables. Female patients had a significantly
better PFS (P¼ .005) and OS (P¼ .031) than males. Having
found significant results for PFS, we separately estimated the
cumulative incidence of local and distant relapse. The local re-
lapse rate was significantly lower in females (5-year cumulative
incidence estimate: 3.4%; 95% CI: 0.9%–13.3%) than in males
(31.8%; 95% CI: 22.9%–44.0%; P, .0001), while for distant
metastases there was no significant difference between the 2
groups, with 16.3% (95% CI: 8.8%–30.1%) in females, and
12.4% (95% CI: 7.1%–21.7%) in males (P¼ .597).
There were no significant differences in PFS by patients’ age,
but the 2 groups (,3 vs ≥3 y old) differed significantly in terms
of OS (Table 2). PFS did not differ significantly by tumor location
either (infratentorial vs supratentorial), whereas OS did (P¼
.039). PFS was significantly better for grade II tumor patients
without residual disease than for grade III tumor patients
with or without residues, while the latter shared much the
same PFS (Fig. 3A; P¼ .025); the OS also differed significantly
between these 3 groups (see different curves in Fig. 3B; P¼
.007). Figure 1B shows the pattern of tumor relapse: there
was no significant difference as regards local relapse (P¼
.309; Supplementary Fig. S1), but patients with residual disease
after surgery had the highest incidence of local recurrence
(5-year estimate: 28.9%; 95% CI: 17.6%–47.4%), followed by
grade III tumor patients without residues (19.4%; 11.3%–
33.5%) and grade II patients without residues (13.5%; 5.8%–
31.7%). Distant relapses were significantly more common
among patients with grade III tumors—whether they were
without residues (18.7%; 10.8%–32.1%) or with residual dis-
ease (17.9%; 9.4%–34.1%)—than in grade II patients without
residues (2.3%; 0.3%–16.9%) (P¼ .048). Considering grade in-
fluence on patients’ PFS and OS according to tumor location,
neither PFS nor OS was influenced in supratentorial tumor pa-
tients. There was instead a statistically significant difference for
patients whose tumor originated infratentorially in both PFS
(5-year estimate: 73.3%, 95% CI: 61.0%–88.2% if grade II;
and 47.8%, 95% CI: 35.0%–65.2% if grade III, P¼ .0047)
and OS (5-year estimate: 89.7%, 95% CI: 81.5%–98.7% if
grade II; and 65.1%, 95% CI: 52.1%–81.4% if grade III, P¼
.009).
Considering the patients’ status before RT, with a further 10
patients becoming disease free after chemotherapy and
second-look surgery, the PFS and OS differed statistically be-
tween the 120 patients who were NED and the 40 who were
still ED. The 5-year estimates for local relapse were 16.9%
Table 2. Kaplan–Meier PFS and OS
PFS OS
5-y Estimate (CI) P (log-rank) 5-y Estimate (CI) P (log-rank)
Gender .005 .031
Female 80.3% (70.4%–91.6%) 89.3% (81.5%–97.8%)
Male 55.8% (45.9%–67.9%) 75.7% (66.6%–86.0%)
Age .164 .035
,3 y 57.6% (43.1%–77.2%) 70.3% (56.3%–87.8%)
≥3 y 67.9% (59.3%–77.8%) 84.8% (77.9%–92.3%)
Tumor location .116 .039
Infratentorial 60.9% (51.4%–72.2%) 77.7% (69.4%–87.0%)
Supratentorial 73.8% (61.9%–87.9%) 88.1% (78.8%–98.6%)
Residual disease after surgery .025 .007
No residual grade II 84.1% (72.9%–97.0%) 97.6% (93.1%–100.0%)
No residual grade III 61.9% (50.3%–76.1%) 79.1% (68.6%–91.2%)
Residual, any grade 53.1% (39.7%–71.0%) 68.6% (55.7%–84.6%)
Status before radiation therapy .011 .001
NED 72.1% (63.8%–81.5%) 87.8% (81.5%–94.6%)
ED 45.3% (30.9%–66.2%) 61.2% (46.5%–80.5%)
WHO grade .018 .031
Grade II/classic 75.3% (64.9%–87.3%) 90.5% (83.4%–98.1%)
Grade III/anaplastic 57.0% (46.7%–69.6%) 73.3% (63.5%–84.6%)
Ventricular shunt .349 .019
No 68.9% (59.8%–79.4%) 85.7% (78.4%–93.6%)
Yes 58.4% (45.5%–74.9%) 72.5% (60.6%–86.6%)
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(95% CI: 10.8%–26.4%) in NED patients and 32.5% (95% CI:
19.5%–54.0%) in still-ED patients (P¼ .119). The correspond-
ing cumulative incidence estimates for distant metastases
were 11.1% (95% CI: 6.5%–18.9%) and 22.3% (95% CI:
11.9%–41.9%) (P¼ .105).
When the 2 children who achieved NED status after RT boost
were included, there were 23 patients who came to have NED
after accrual thanks to multiple surgical procedures and che-
motherapy; their prognoses, in terms of both PFS and OS,
were much the same as for patients who had NED after a single
excision (data not shown).
Among the 40 patients with ED before RT, 24 received the
prescribed boost after the standard course of radiation
(Fig. 1B): the 5-year estimates for PFS were 58.1% (95% CI:
39.1%–86.4%) for the latter 24 patients, and 43.0% (95%
CI: 43.0%–78.6%) for the 16 not given the boost (P¼ .344),
while the OS estimates were 68.7% (95% CI: 50.5%–93.4%)
versus 50.2% (95% CI: 29.8%–84.6%) (P ¼ .346). A WHO
grade II classic ependymoma was associated with the best
PFS and OS in our sample: the PFS was 75.3% (95% CI:
64.9%–87.3%) and 57.0% (95% CI: 46.7%–69.6%) for
grade II and grade III tumor patients, respectively (P ¼
.018); and the OS was 90.5% (95% CI: 86.8%–98.1%) and
73.3% (95% CI: 63.5%–84.6%) for grade II and grade III
tumor patients, respectively (P¼ .031). The 5-year estimates
for local relapse were 17.3% (95% CI: 9.6%–31.0%) in the
grade II subgroup and 23.7% (95% CI: 15.6%–35.9%) for pa-
tients with ED (P¼ .281). The corresponding cumulative inci-
dence estimates for distant metastases were 7.4% (95% CI:
3.2%–17.5%) and 19.3% (95% CI: 12.1%–30.6%) (P¼ .052).
Among the 45 patients aged below 3 years at diagnosis, 16
had grade II tumors. Differently from older children, their
PFS and OSwere not significantly better than those of children
with grade III tumors.
Table 3 shows the results of Cox’s multivariate analysis, after
selecting prognostic variables with the boosting algorithm. The
most influential variables identified by the algorithm were the
same on both of the endpoints considered, but tumor grade
had themost influence on PFS, followed by gender, NED/ED sta-
tus before RT, and tumor location; as for OS, the most influen-
tial variable was NED/ED status before RT, followed by tumor
grade, tumor location, and gender.
Discussion
After the previous Italian experience showing quite a good
prognosis for completely resected classic ependymoma,6
Fig. 3. (A) Kaplan-Meier PFS and (B) OS curves by outcome of first
surgery.
Table 3. Cox multivariate model analyses of PFS and OS
PFS OS
Hazard Ratio (CI) P (Wald test) Hazard Ratio (CI) P (Wald test)
Gender .063 .251
Male vs female 1.93 (0.96, 3.86) 1.72 (0.68, 4.37)
Tumor location .186 .076
Infratentorial vs supratentorial 1.59 (0.80, 3.14) 2.47 (0.91, 6.72)
Status before radiation therapy .058 .009
ED vs NED 1.78 (0.98, 3.22) 2.73 (1.28, 5.83)
WHO grade .012 .009
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efforts were made to improve the strategies for patients with
residual disease and for the children whose prognoses re-
mained poor even after a complete resection, that is, those
with anaplastic ependymoma.8,16 Given the renewed interest
in RT in recent years, with the advent of more sophisticated
RT planning and delivery techniques, allowing a dose reduc-
tion to normal tissues and improving clinical results (as de-
scribed mainly in several publications by T. Merchant and
colleagues7,8), including a reasonably satisfactory neurocog-
nitive outcome even in the pluri-operated and the youngest
children,17 we applied the same approach to children under
3 years old.
As already reported,18 second-look surgical procedures
were undertaken on a national scale in both the first6 and
this subsequent protocol, achieving a complete resection
rate of 75%without significant additional morbidity. This per-
centage comes very close to the 125/158 cases reported by
Merchant in 20098 and compares favorably with other expe-
riences,19 – 21 raising hopes that a larger percentage of chil-
dren may be cured. Optimal local tumor control was further
pursued by using higher doses of radiation and adding hypo-
fractionated 8-Gy boosts to local residues after surgery. At
the time of writing the protocol, and more recently too,
some authors were beginning to demonstrate the activity
of high-dose local radiation in a few patients with residual
or recurrent ependymoma. They reported achieving local
control rates as high as 70%, albeit always with short follow-
ups and smaller series than the one described here.22 –25 In
our series, the 24 patients receiving the RT boost had a
5-year PFS higher than 58% and, for the whole group of pa-
tients with ED, it was over 53% compared with 35% in our
previous report,6 41% for the St Jude series,8 and ,30%
with the Children’s Cancer Group protocol 9942,21 which
are the largest and most recent series. The difference
vis-a`-vis the patients achieving a complete resection persist-
ed, however, on univariate analysis for both PFS and OS, and
on multivariate analysis for OS.
We added VEC chemotherapy after RT for patients with
completely resected anaplastic ependymomas, who had a
worse prognosis than those with completely resected classic
WHO grade II tumors in our own previous series and in those
of others.8,26 The German Hirntumoren (HIT) trials had ob-
tained the best results in this subset of patients by using ad-
juvant chemotherapy with sandwich or post-RT courses.26
Our protocol was not as successful in the 2 subgroups of
patients with different tumor grades but the same surgical
results: the outcome for the 2 populations remained signifi-
cantly different. The role of adjuvant chemotherapy in epen-
dymoma will only be definitively ruled out, however, after the
completion of the randomized trial by the International Soci-
ety of Paediatric Oncology (SIOP), which is investigating this
issue.
The prognosis for children under 3 years old did not differ sig-
nificantly, in terms of PFS, from that of older children treated ac-
cording to the same protocol, but their OSwas lower. Thismay be
because the younger children were offered a less aggressive sec-
ond treatment at relapse, whereas nowadays there is a tendency
to perform further excisions and to repeat irradiation.27–29 The
use of chemotherapy-only protocols in young patients achieved
very low PFS and high re-treatment rates,19,30,31 and—barring
exceptional cases—it should be abandoned, especially now
that experiences of good neurofunctional outcomes after first-
line irradiation have been confirmed.8
The better prognosis for female patients had already been
noted8,32 and correlated with a lower local relapse rate, but
not with any other significant prognostic factors. A better prog-
nosis for female patients had already been described in high-
grade glioma.33 To our knowledge, this rather peculiar differ-
ence in outcome has yet to be studied, but a correlation with
still hidden biological differences between the genders has
been hypothesized.
As in our previous protocol and subsequent papers,6,20,34
we again found a strong prognostic impact of tumor grade,
even on multivariate analysis. Despite inconsistency in other
national series, the prognostic significance of tumor grade in
our previous series was also confirmed in a multinational
pathological review.16 It is now clear that the impact of his-
tology can emerge only if well-characterized clinical cohorts
of sufficient size are selected, and relevant and reproducible
histological criteria are adopted.16,35,36 In particular, given
the efforts to provide optimal adjuvant radiotherapy, it is
tempting to speculate that the impact of histology detected
in Italian series may relate to different radiosensitivity of
WHO grade II versus grade III ependymoma.
In conclusion, in a national multi-institutional setting, and
in the largest sample of ependymoma patients to be included
in a prospective trial to date, we have demonstrated the fea-
sibility of multiple surgical procedures followed by a novel
radiotherapeutic approach, with a trend to outcome amelio-
ration in children with residual disease, a patient group that
carries a poor prognosis. A limitation of this study is the
lack of complete observations on neurocognitive outcome,
even if some evaluations have been published.37 The recently
opened SIOP trial will try, as did the previously open COG-
ACNS0831 trial, to shed light on the usefulness of adjuvant
chemotherapy in patients with completely resected tumors.
The significance of factors repeatedly shown to be prognos-
tic will be further analyzed in the light of genomic and mo-
lecular studies on the same series of patients in an effort to
elucidate how they may be subgrouped differently, also with
a view to sparing certain patient categories from adjuvant
treatment.
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efforts were made to improve the strategies for patients with
residual disease and for the children whose prognoses re-
mained poor even after a complete resection, that is, those
with anaplastic ependymoma.8,16 Given the renewed interest
in RT in recent years, with the advent of more sophisticated
RT planning and delivery techniques, allowing a dose reduc-
tion to normal tissues and improving clinical results (as de-
scribed mainly in several publications by T. Merchant and
colleagues7,8), including a reasonably satisfactory neurocog-
nitive outcome even in the pluri-operated and the youngest
children,17 we applied the same approach to children under
3 years old.
As already reported,18 second-look surgical procedures
were undertaken on a national scale in both the first6 and
this subsequent protocol, achieving a complete resection
rate of 75%without significant additional morbidity. This per-
centage comes very close to the 125/158 cases reported by
Merchant in 20098 and compares favorably with other expe-
riences,19 – 21 raising hopes that a larger percentage of chil-
dren may be cured. Optimal local tumor control was further
pursued by using higher doses of radiation and adding hypo-
fractionated 8-Gy boosts to local residues after surgery. At
the time of writing the protocol, and more recently too,
some authors were beginning to demonstrate the activity
of high-dose local radiation in a few patients with residual
or recurrent ependymoma. They reported achieving local
control rates as high as 70%, albeit always with short follow-
ups and smaller series than the one described here.22 –25 In
our series, the 24 patients receiving the RT boost had a
5-year PFS higher than 58% and, for the whole group of pa-
tients with ED, it was over 53% compared with 35% in our
previous report,6 41% for the St Jude series,8 and ,30%
with the Children’s Cancer Group protocol 9942,21 which
are the largest and most recent series. The difference
vis-a`-vis the patients achieving a complete resection persist-
ed, however, on univariate analysis for both PFS and OS, and
on multivariate analysis for OS.
We added VEC chemotherapy after RT for patients with
completely resected anaplastic ependymomas, who had a
worse prognosis than those with completely resected classic
WHO grade II tumors in our own previous series and in those
of others.8,26 The German Hirntumoren (HIT) trials had ob-
tained the best results in this subset of patients by using ad-
juvant chemotherapy with sandwich or post-RT courses.26
Our protocol was not as successful in the 2 subgroups of
patients with different tumor grades but the same surgical
results: the outcome for the 2 populations remained signifi-
cantly different. The role of adjuvant chemotherapy in epen-
dymoma will only be definitively ruled out, however, after the
completion of the randomized trial by the International Soci-
ety of Paediatric Oncology (SIOP), which is investigating this
issue.
The prognosis for children under 3 years old did not differ sig-
nificantly, in terms of PFS, from that of older children treated ac-
cording to the same protocol, but their OSwas lower. Thismay be
because the younger children were offered a less aggressive sec-
ond treatment at relapse, whereas nowadays there is a tendency
to perform further excisions and to repeat irradiation.27–29 The
use of chemotherapy-only protocols in young patients achieved
very low PFS and high re-treatment rates,19,30,31 and—barring
exceptional cases—it should be abandoned, especially now
that experiences of good neurofunctional outcomes after first-
line irradiation have been confirmed.8
The better prognosis for female patients had already been
noted8,32 and correlated with a lower local relapse rate, but
not with any other significant prognostic factors. A better prog-
nosis for female patients had already been described in high-
grade glioma.33 To our knowledge, this rather peculiar differ-
ence in outcome has yet to be studied, but a correlation with
still hidden biological differences between the genders has
been hypothesized.
As in our previous protocol and subsequent papers,6,20,34
we again found a strong prognostic impact of tumor grade,
even on multivariate analysis. Despite inconsistency in other
national series, the prognostic significance of tumor grade in
our previous series was also confirmed in a multinational
pathological review.16 It is now clear that the impact of his-
tology can emerge only if well-characterized clinical cohorts
of sufficient size are selected, and relevant and reproducible
histological criteria are adopted.16,35,36 In particular, given
the efforts to provide optimal adjuvant radiotherapy, it is
tempting to speculate that the impact of histology detected
in Italian series may relate to different radiosensitivity of
WHO grade II versus grade III ependymoma.
In conclusion, in a national multi-institutional setting, and
in the largest sample of ependymoma patients to be included
in a prospective trial to date, we have demonstrated the fea-
sibility of multiple surgical procedures followed by a novel
radiotherapeutic approach, with a trend to outcome amelio-
ration in children with residual disease, a patient group that
carries a poor prognosis. A limitation of this study is the
lack of complete observations on neurocognitive outcome,
even if some evaluations have been published.37 The recently
opened SIOP trial will try, as did the previously open COG-
ACNS0831 trial, to shed light on the usefulness of adjuvant
chemotherapy in patients with completely resected tumors.
The significance of factors repeatedly shown to be prognos-
tic will be further analyzed in the light of genomic and mo-
lecular studies on the same series of patients in an effort to
elucidate how they may be subgrouped differently, also with
a view to sparing certain patient categories from adjuvant
treatment.
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